AB 575 — the Obesity Prevention Treatment Parity Act — amends California’s Health and Safety Code and Insurance Code to require group and individual health plans and policies that include outpatient prescription drug benefits to cover, without prior authorization, at least one FDA‑approved anti‑obesity medication (explicitly including GLP‑1 receptor agonists) and intensive behavioral therapy for obesity. The mandate applies to contracts and policies issued, amended, or renewed on or after January 1, 2026, and exempts dental‑only, vision‑only, and Medicare supplement products.
The bill aims to broaden access to pharmacologic and behavioral obesity treatments and to close equity gaps identified in its legislative findings. It constrains payers’ ability to impose pre‑authorization barriers and prevents coverage criteria from being stricter than FDA indications, while still allowing insurers to use utilization management tools to judge medical necessity on the same terms they apply to other conditions.
At a Glance
What It Does
The bill adds mirrored requirements to the Health and Safety Code (section 1374.6) and the Insurance Code (section 10123.62) obligating group and individual plans with outpatient prescription drug benefits to cover at least one FDA‑approved anti‑obesity medication and intensive behavioral therapy without prior authorization for contracts issued, amended, or renewed on or after January 1, 2026. It bars coverage criteria that are more restrictive than FDA‑approved indications but still permits utilization management applied consistently with other conditions.
Who It Affects
Covered entities are commercial health care service plans regulated under the Health and Safety Code and health insurers regulated under the Insurance Code that provide outpatient prescription drug benefits. The text excludes dental‑only, vision‑only plans and Medicare supplement policies; it does not change treatment coverage for self‑funded ERISA plans (which are governed by federal law).
Why It Matters
This bill forces payers to offer pharmacologic obesity treatment as a standard covered benefit, potentially increasing patient access to GLP‑1RAs and related therapies while prompting payers to revisit formularies, cost‑sharing, and utilization controls. It is a narrow but meaningful statutory parity move that shifts administrative barriers (prior authorization) and sets a ceiling on coverage restrictiveness tied to FDA labeling.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 575 creates a statutory floor for coverage of obesity treatment in California’s regulated commercial market. It requires that when a group or individual health plan/policy includes outpatient prescription drug benefits, the plan must include coverage without prior authorization for at least one FDA‑approved medication indicated for chronic weight management and for intensive behavioral therapy.
The bill repeats the requirement in two places — one directed at plans under the Health and Safety Code and the other at policies under the Insurance Code — so it applies to both major state‑regulated product types.
The statute is precise about timing: it affects contracts and policies issued, amended, or renewed on or after January 1, 2026. At the same time, it preserves insurer discretion to apply utilization management to determine medical necessity, provided those determinations are made in the same manner as for any other illness covered by the contract.
The bill also states that coverage criteria for FDA‑approved anti‑obesity medications must not be more restrictive than the FDA‑approved indications for those treatments, effectively limiting payers from imposing eligibility thresholds that go beyond the drug label.Several practical ambiguities arise from the text. The bill removes prior authorization as a prerequisite for coverage but still allows utilization management; payers can therefore rely on other tools (step therapy, quantity limits, specialty tiers, clinical criteria) framed as medical‑necessity determinations.
The statute does not define "intensive behavioral therapy," nor does it specify benefit design (cost‑sharing levels, duration of therapy, or whether behavioral therapy must be provided by a credentialed obesity specialist), leaving implementation details to plan design and regulator interpretation. The text also lacks enforcement provisions or penalties tied to noncompliance, creating uncertainty about how the Department of Managed Health Care or the California Department of Insurance will monitor and enforce the new requirements.Finally, the bill is targeted: it excludes dental‑only and vision‑only products and Medicare supplement plans, and it does not alter federal ERISA preemption.
That means many large employer self‑insured plans are likely outside the statute’s reach, while fully insured commercial products in California will face the direct effects of the mandate. Payers, providers, and manufacturers will need to reconcile clinical practice, formulary management, and premium impacts when implementing the law.
The Five Things You Need to Know
Effective date: the coverage requirement applies to group and individual plans and policies issued, amended, or renewed on or after January 1, 2026.
No prior authorization: plans must include coverage for at least one FDA‑approved anti‑obesity medication and intensive behavioral therapy without requiring prior authorization.
Utilization management allowed: insurers may still apply utilization management and medical‑necessity determinations so long as they use the same standards they apply to other illnesses.
Coverage ceiling tied to FDA labeling: coverage criteria for FDA‑approved anti‑obesity drugs may not be more restrictive than the FDA‑approved indications for those drugs.
Scope and exemptions: the bill inserts identical obligations into the Health and Safety Code (1374.6) and Insurance Code (10123.62), and it exempts dental‑only, vision‑only, and Medicare supplement products; self‑insured ERISA plans remain governed by federal law and are likely unaffected.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Legislative findings on obesity and equity
This section lists medical and socioeconomic findings: obesity is identified as a chronic disease by major medical organizations, correlates with many comorbidities and certain cancers, and disproportionately affects communities of color and low‑income Californians. The findings function as the policy rationale for parity: they frame obesity as a medical condition that warrants comparable coverage to other chronic diseases and highlight equity gaps that the bill intends to address.
Plan requirement for health care service plans
Adds a new §1374.6 requiring group or individual health care service plan contracts that include outpatient prescription drug benefits to cover, without prior authorization, at least one FDA‑approved anti‑obesity medication (including GLP‑1RAs) and intensive behavioral therapy for obesity when contracts are issued, amended, or renewed on or after January 1, 2026. The subsection permits utilization management and ties allowable coverage criteria to FDA indications, defines key terms, and excludes dental‑only, vision‑only, and Medicare supplement plans. Practically, this places a compliance obligation on plans regulated by the Department of Managed Health Care to adjust formularies and benefit documents and to justify any utilization controls under the same standards used for other conditions.
Policy requirement for health insurers
Creates a parallel provision in the Insurance Code, imposing identical obligations on health insurance policies regulated by the California Department of Insurance. The duplication ensures the mandate covers both DMHC‑regulated managed care products and CDI‑regulated indemnity/HMO products. Insurers will need to update policy forms, disclosure documents, and utilization protocols; like the Health & Safety Code provision, the statute limits additional restrictions beyond FDA labeling but leaves room for medical‑necessity reviews handled consistently with other benefits.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Californians with obesity, especially those who lack prior access to pharmacologic treatment: the mandate reduces administrative barriers (removes prior authorization) and expands the set of covered options to include at least one FDA‑approved anti‑obesity medication and intensive behavioral therapy.
- Patients in low‑income and communities of color: the bill’s findings and statutory parity aim to close access gaps that are partly driven by affordability and administrative barriers, potentially improving equitable access where commercial plans are the payer.
- Obesity specialists and behavioral health providers: increased coverage for intensive behavioral therapy and anti‑obesity drugs may raise demand for specialty care, interdisciplinary treatment plans, and ongoing follow‑up services.
- Manufacturers of FDA‑approved anti‑obesity medications (including GLP‑1RAs): statutory coverage mandates can expand the commercial market and reduce reliance on case‑by‑case coverage decisions.
Who Bears the Cost
- Fully insured commercial health plans and insurers regulated by California (DMHC and CDI): they will assume increased benefit costs and administrative work to revise formularies, policy forms, and utilization protocols; those costs may feed into premium adjustments.
- Employers with fully insured plans: premiums passed through to employers for fully insured group products may rise as coverage expands, while self‑insured employers (ERISA plans) may be unaffected.
- State regulatory agencies (DMHC and CDI): regulators will face interpretation and oversight responsibilities without explicit new funding or enforcement mechanisms in the text.
- Pharmacy benefit managers and plan pharmacy administrators: PBMs may need to rework prior authorization rules, formulary tiers, and quantity limits to conform to the statute’s prior‑authorization and FDA‑indication constraints.
Key Issues
The Core Tension
The central dilemma is access versus resource control: the bill expands timely access to clinically effective but costly obesity treatments by removing prior‑authorization barriers and tying eligibility to FDA labeling, yet expanding coverage creates immediate cost pressure for payers and employers. Payers can respond by raising premiums, shifting costs to patients through higher copays or coinsurance, or substituting other utilization controls—actions that may reintroduce access barriers the statute seeks to remove.
Several implementation gaps and trade‑offs could blunt the bill’s intended effect. The statute removes prior authorization but simultaneously allows utilization management and medical‑necessity determinations, which are often operationalized through mechanisms like step therapy, quantity limits, clinical criteria, or specialty tiers.
Insurers can therefore restrict access through non‑prior‑auth controls unless regulators or courts interpret the statute to treat those tools as equivalent to prior authorization. The bill’s prohibition that coverage criteria not be more restrictive than FDA indications sets a legal boundary, but FDA labels themselves often include BMI or comorbidity thresholds; in practice, plans might rely on those labels to set tight eligibility while arguing they comply with the statute.
Key terms are undefined and consequential. The statute requires coverage for "intensive behavioral therapy" without a statutory definition, leaving ambiguity over session counts, provider qualifications, telehealth delivery, and whether group versus individual therapy is covered.
The law also lacks explicit rules about cost‑sharing, duration of coverage, reauthorization intervals, or whether concurrent coverage should be provided for patients using anti‑obesity drugs for other FDA indications (for example, when a GLP‑1RA is prescribed for type 2 diabetes). Finally, the bill contains no enforcement mechanism or specified remedies for noncompliance; absent regulatory guidance, payers may comply in letter but not in spirit, and affected patients may need to rely on administrative complaints or litigation to press unresolved issues.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.